CJC-1295 vs Ipamorelin: Two Pathways to Growth Hormone Research
By Peptura Research Team/9 March 2025/9 min read
Two Secretagogues, One Endpoint
CJC-1295 and Ipamorelin are among the most thoroughly studied growth hormone secretagogues in preclinical research. Each prompts growth hormone release, but they do so through different receptors and carry very different pharmacokinetic profiles. Getting that distinction clear is essential for anyone designing protocols around growth hormone signalling, and especially for work looking at combined or synergistic effects.
CJC-1295 in Detail
CJC-1295 is a synthetic analogue of growth hormone releasing hormone (GHRH). Built from 29 amino acids, it acts as a GHRH receptor agonist, prompting the pituitary directly to produce and release growth hormone. Its defining trait is a long half-life, achieved by a modification that lets it bind serum albumin and so remain active far longer than native GHRH, which makes it well suited to research on sustained growth hormone signalling.
It has a molecular weight of roughly 3,367 Da and comes in two forms: with DAC (Drug Affinity Complex), which gives the extended half-life, and without DAC, which acts over a shorter window. Research-grade CJC-1295 is usually supplied as the DAC form unless stated otherwise.
Ipamorelin in Detail
Ipamorelin is a synthetic pentapeptide and a selective ghrelin receptor agonist, acting at the growth hormone secretagogue receptor (GHS-R). Rather than working through the GHRH receptor as CJC-1295 does, it copies ghrelin, binding the same receptor to trigger growth hormone release. With just 5 amino acids it is a far smaller molecule, around 711 Da.
Selectivity is its signature. Ipamorelin drives growth hormone release without meaningfully disturbing cortisol or prolactin in research models, in contrast to some other ghrelin mimetics such as GHRP-6 or GHRP-2. That clean profile has made it a favourite for isolating growth hormone signalling.
GHRH Pathway vs Ghrelin Pathway
The core difference between the two peptides is which receptor they hit and how the signal travels:
CJC-1295 (GHRH pathway): Binds GHRH receptors on pituitary somatotroph cells and drives synthesis and release of growth hormone through the cAMP cascade. This is the 'direct' arm of growth hormone regulation and closely tracks the body's own GHRH signalling.
Ipamorelin (ghrelin pathway): Binds the ghrelin receptor (GHS-R1a) and triggers release through a separate route involving calcium and protein kinase C signalling, an alternative lever on growth hormone secretion.
Because the two run through different receptors and different intracellular cascades, combining them can produce synergy. That complementarity is the whole rationale behind paired CJC-1295 and Ipamorelin protocols.
Kinetics and Duration
CJC-1295 with DAC carries an extended half-life of roughly 6 to 8 days in research models, thanks to its albumin binding. Less frequent dosing and a sustained elevation of growth hormone follow from that.
Ipamorelin sits at the opposite end, with a half-life around 2 hours and a correspondingly quick rise and fall in growth hormone. That pulsatile shape is closer to the body's own secretion rhythm and can be an advantage where transient signalling is the point.
Those contrasting kinetics are exactly why the two work as complements. CJC-1295 lifts the baseline; Ipamorelin adds short pulses on top; together they produce a pattern some researchers believe more faithfully mirrors physiological growth hormone dynamics.
Research Applications
Both peptides feature heavily across growth hormone biology, metabolic research, body-composition models, and tissue-repair pathways. Common areas include:
• Growth hormone secretion dynamics and pulsatility
• IGF-1 signalling pathway research
• Metabolic regulation and energy expenditure models
• Muscle and connective tissue biology
• Bone density and skeletal research models
• Ageing biology and age-related hormone decline
• Neuroprotection and cognitive function models
CJC-1295 earns its place where sustained growth hormone elevation is required; Ipamorelin is preferred for acute, pulsatile signalling, or wherever selectivity with minimal cortisol and prolactin effect matters.
Why Labs Pair Them
The CJC-1295 and Ipamorelin combination is one of the most frequently used in growth hormone research, and the logic rests on their complementary mechanisms:
1. Dual pathway activation: Stimulating GHRH and ghrelin receptors together yields greater growth hormone output than either pathway alone in research models.
2. Baseline plus pulses: CJC-1295 holds a sustained baseline while Ipamorelin layers physiological pulses on top.
3. Receptor sensitisation: Some research suggests that alternating secretagogue mechanisms may limit the receptor downregulation seen with chronic single-pathway stimulation.
Combined protocols typically deliver both peptides in the same timeframe, though not necessarily in the same injection. Calculate concentrations separately and keep handling sterile throughout.
Reconstitution and Handling
Both CJC-1295 and Ipamorelin arrive as lyophilised white powders. Hold at -20°C before reconstitution. Both are reconstituted with bacteriostatic water for research use:
1. Bring vials to room temperature
2. Sterilise rubber stoppers with alcohol swabs
3. Run bacteriostatic water slowly down the inner vial wall
4. Swirl gently, never shake, until fully dissolved
5. Store the reconstituted solution at +4°C
6. Use within four weeks of reconstitution
For a fuller walkthrough see our complete peptide reconstitution guide, or run the numbers with the free Peptura reconstitution calculator.
Sourcing CJC-1295 and Ipamorelin in the UK
Peptura supplies research-grade CJC-1295 (with DAC) and Ipamorelin as lyophilised powders from GMP-certified manufacturers, each with full batch documentation and HPLC verification. Both ship UK-wide and internationally via tracked delivery, with cold-chain storage maintained throughout. All products are strictly for laboratory and in-vitro research use only.
Related Products
Disclaimer: This article is for research and educational purposes only. All information provided is not intended as medical advice. Peptura products are not for human consumption and are sold strictly for laboratory research use only.